EUVIMEDEUVIMED entdecken
Open Access

A STING agonist potentiates C1 lipidoid-based mRNA cancer vaccine through promoting TNF-α secretion in vivo

Hongxia Zhang, Yang Lin, Liying Wang, Lei Cui, Zining Wang, Xinru You, Chunyuan Xie, Huanling Zhang, Yongxiang Liu, Mengyun Li, Xiaojuan Wang, Jun Wu und 1 weitere

Molecular Therapy · 2026-01 · 34 (1) · 315-329

DOI: 10.1016/j.ymthe.2025.09.032 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Therapy, 2026-01. Verfasst von Hongxia Zhang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Nanfang Hospital, School of Basic Medical Sciences, Southern Medical University, Guangzhou 510515, China; State Key Laborato…. Hauptthemen laut MEDLINE: Membrane Proteins, Cancer Vaccines, Tumor Necrosis Factor-alpha, RNA, Messenger. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Basic and Applied Basic Research Foundation of Guangdong Province, Guangzhou Municipal Science and Technology Program key projects, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Intracellular delivery of antigen-encoding mRNA-based vaccine has shown great potential in the treatment of cancer and infectious diseases. We previously developed a minimalist cancer nanovaccine using C1 lipidoid nanoparticle with self-adjuvant activity, which markedly improves mRNA delivery and antigen presentation through TLR4 signaling activation. Although the C1-mRNA nanovaccine induced strong antitumor efficiency in prophylactic and therapeutic settings, it could not eliminate tumors with low immunogenicity. To further improve the therapeutic efficacy of the mRNA vaccine, we screened several innate immune receptor agonists and identified the STING agonist as an effective adjuvant for C1-mRNA vaccine, which could effectively promote the production of type I interferon and pro-inflammatory cytokines including IL-12 and TNF-α in dendritic cells. Such a C1-mRNA cancer vaccine adjuvanted with STING agonist effectively promoted antigen presentation in dendritic cells and enhanced T cell activation and exhibited strong antitumor activity on tumor models. Mechanistically, this mRNA vaccine showed improved antitumor efficacy largely depending on STING protein expression in dendritic cells and TNF-α induction in vivo, while type I interferon or IL-12 induction seemed dispensable. Together, by optimizing the antitumor efficacy of C1-mRNA cancer vaccine with STING agonist, this work provides a potential mRNA cancer vaccine platform for treating a wide range of tumor types.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Membrane ProteinsCancer VaccinesTumor Necrosis Factor-alphaRNA, MessengermRNA VaccinesAnimalsMiceDendritic CellsHumansCell Line, TumorLipidsNanoparticlesAntigen PresentationMice, Inbred C57BLFemaleSTING Protein

Stichwörter der Autor:innen

C1-mRNA cancer vaccineSTING agonistTNF-αcancer immunotherapyinnate immunity

Substanzen

Membrane ProteinsCancer VaccinesTumor Necrosis Factor-alphaRNA, MessengermRNA VaccinesLipidsSting1 protein, mouseSTING Protein

Autor:innen und Institutionen

  • Department of Pathology, Nanfang Hospital, School of Basic Medical Sciences, Southern Medical University, Guangzhou 510515, China; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Can…
  • Department of Pathology, Nanfang Hospital, School of Basic Medical Sciences, Southern Medical University, Guangzhou 510515, China.
  • Department of Anesthesiology, General Hospital of Southern Theatre Command of PLA, Guangzhou 510010, China.
  • State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
  • Center for Nanomedicine and Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
  • MOE Key Laboratory of Gene Function and Regulation, State Key Laboratory of Biocontrol, School of Life Sciences, Sun Yat-sen University, Guangzhou 510275, China.

Förderung

  • Basic and Applied Basic Research Foundation of Guangdong Province
  • Guangzhou Municipal Science and Technology Program key projects
  • National Natural Science Foundation of China

Zitieren

APA

Zhang, H., Lin, Y., Wang, L., Cui, L., Wang, Z., You, X., Xie, C., Zhang, H., Liu, Y., Li, M., Wang, X., Wu, J., & Xia, X. (2026). A STING agonist potentiates C1 lipidoid-based mRNA cancer vaccine through promoting TNF-α secretion in vivo. Molecular Therapy, 34(1), 315-329. https://doi.org/10.1016/j.ymthe.2025.09.032

Vancouver

Zhang H, Lin Y, Wang L, Cui L, Wang Z, You X, et al. A STING agonist potentiates C1 lipidoid-based mRNA cancer vaccine through promoting TNF-α secretion in vivo. Molecular Therapy. 2026;34(1):315-329. doi:10.1016/j.ymthe.2025.09.032

BibTeX
@article{Zhang2026,
  author = {Zhang, Hongxia and Lin, Yang and Wang, Liying and Cui, Lei and Wang, Zining and You, Xinru and Xie, Chunyuan and Zhang, Huanling and Liu, Yongxiang and Li, Mengyun and Wang, Xiaojuan and Wu, Jun and Xia, Xiaojun},
  title = {A STING agonist potentiates C1 lipidoid-based mRNA cancer vaccine through promoting TNF-α secretion in vivo},
  journal = {Molecular Therapy},
  year = {2026},
  volume = {34},
  number = {1},
  pages = {315--329},
  doi = {10.1016/j.ymthe.2025.09.032}
}
Kostenlos starten →